KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Research & Development (2017 - 2025)

Historic Research & Development for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to -$1.1 billion.

  • Takeda Pharmaceutical's Research & Development fell 169.31% to -$1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.9 billion, marking a year-over-year decrease of 432.0%. This contributed to the annual value of $4.8 billion for FY2025, which is 528.61% down from last year.
  • Takeda Pharmaceutical's Research & Development amounted to -$1.1 billion in Q4 2025, which was down 169.31% from -$1.1 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's Research & Development's 5-year high stood at $8.5 billion during Q1 2024, with a 5-year trough of -$1.3 billion in Q3 2023.
  • Over the past 5 years, Takeda Pharmaceutical's median Research & Development value was -$1.1 billion (recorded in 2021), while the average stood at $226.0 million.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Research & Development tumbled by 11638.22% in 2022, and later surged by 79342.58% in 2024.
  • Takeda Pharmaceutical's Research & Development (Quarter) stood at -$1.1 billion in 2021, then decreased by 9.45% to -$1.2 billion in 2022, then decreased by 2.56% to -$1.3 billion in 2023, then increased by 11.69% to -$1.1 billion in 2024, then dropped by 1.69% to -$1.1 billion in 2025.
  • Its last three reported values are -$1.1 billion in Q4 2025, -$1.1 billion for Q3 2025, and -$994.4 million during Q2 2025.